Neurocrine Biosciences (NBIX) Interest Coverage Ratio Growth (3y) (2020 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Interest Coverage Ratio Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn | -1.75% |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn | - |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn | -7.51% |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn | -26.54% |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn | 59.44% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 75.30% |
| 10 | Neurocrine Biosciences | 15.59 Bn | 15.20 Bn | 935.80 Mn | -2.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.64% |
| Mar 31, 2024 | 163.72% |
| Dec 31, 2023 | 145.76% |
| Sep 30, 2023 | 198.62% |
| Jun 30, 2023 | 83.06% |
| Mar 31, 2023 | -154.34% |
| Dec 31, 2022 | 150.90% |
| Sep 30, 2022 | 86.59% |
| Jun 30, 2022 | 78.74% |
| Mar 31, 2022 | 27.92% |
| Dec 31, 2021 | -58.12% |
| Sep 30, 2021 | -1.62% |
| Jun 30, 2021 | 251.74% |
| Mar 31, 2021 | 44.00% |
| Dec 31, 2020 | 79.37% |
| Sep 30, 2020 | -85.45% |
| Jun 30, 2020 | 40.41% |